The estimated Net Worth of Adrian N Hobden is at least $7.18 Milion dollars as of 8 June 2009. Adrian Hobden owns over 37,158 units of Myriad Genetics stock worth over $6,151,386 and over the last 22 years Adrian sold MYGN stock worth over $1,028,100.
Adrian has made over 18 trades of the Myriad Genetics stock since 2004, according to the Form 4 filled with the SEC. Most recently Adrian exercised 37,158 units of MYGN stock worth $399,820 on 8 June 2009.
The largest trade Adrian's ever made was exercising 40,000 units of Myriad Genetics stock on 27 May 2009 worth over $95,600. On average, Adrian trades about 9,132 units every 59 days since 2003. As of 8 June 2009 Adrian still owns at least 234,071 units of Myriad Genetics stock.
You can see the complete history of Adrian Hobden stock trades at the bottom of the page.
Adrian's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum a Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: